Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Orphan Incentives: Voucher Price Drop Gives Some Sponsors 'Pause'

Dec 19 2017

• By Derrick Gingery

Priority Review Voucher

Related Content

Review Voucher Program For Rare Pediatric Diseases Should Not Be Reauthorized, US FDA Says

Mar 03 2016

Priority Review Voucher Expansion Could Be Bad, Program Creator Says

May 13 2016

Priority Review Voucher Sales Prices Level Off In 2017

Nov 27 2017

Orphan Drug Tax Credit Defense Adds To NORD's Legislative Challenges

Nov 02 2017

Orphan Designation Requests To Get Slower Reviews

May 11 2016

FDA's Orphan Designation Backlog Plan Focuses On Efficiency, Not Staff

Jun 29 2017

Orphan Drug Pricing Heading To Negotiating Table in US?

Jun 06 2017

Related Companies

Albireo Pharma Inc.

BioMarin Pharmaceutical Inc.

Novartis AG

Ultragenyx Pharmaceutical Inc.

Additional Topics

United States Rare Diseases Business Strategies Review Pathway Financing FDA Legislation Regulation BioPharmaceutical

More from Rare Diseases

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window